Creators and Guests

With over 30 years in creative marketing and visual storytelling, I’ve built a career on turning ideas into impact. From brand transformation to media production, podcast development, and outreach strategies, I craft compelling narratives that don’t just capture attention—they accelerate growth and drive measurable results.

Aimee Taylor is the founder and CEO of Alt Digital Marketing, a company that specializes in medical marketing with particular emphasis on the aesthetics industry. Aimee has over 13 years of digital marketing experience, which is bolstered by two decades of broadcast TV sales. She has a deep understanding of all aspects of digital and traditional marketing. She has a BA in Telecommunications from Indiana University, Bloomington, IN.

Anna Forsythe, PharmD, MBA, is the Founder and CEO of Oncoscope-AI, the first platform to unify real-time oncology treatment data, clinical guidelines, research, and regulatory approvals—offered free to oncology professionals worldwide and often described as “Expedia for cancer care.” With a background spanning pharmacy, health economics, and executive leadership at Novartis, Bayer, and Eisai, Anna previously co-founded Purple Squirrel Economics (acquired by Cytel in 2020), has taught health economics at Long Island University, and is a frequent industry speaker and author, with her 2022 JAMA Pediatrics article on conversion therapy ranked in the top 5% of all JAMA research outputs worldwide.

Bill Wittmeyer is the Founder and CEO of Maggie’s Breath (formerly Pulmostics Limited) where he applies advanced detection technologies—such as high-speed gas chromatography—to protect human health and the environment. Maggie’s Breath was renamed in honour of Bill’s late wife, Maggie, who lost her battle with breast cancer while working to advance life-saving diagnostics. Her vision lives on through the company’s mission: to create a revolutionary, non-invasive breath-based screening tool that can detect disease early and save lives. Bill’s leadership spans innovations in healthcare, environmental monitoring, and public safety, all driven by a commitment to turning personal loss into global impact for a healthier, more sustainable world.

The idea for Resolve was sparked in 2016, when founder Braden Pan received an outrageous hospital bill for a brief, 15-minute consultation. Frustrated by the complex and opaque billing process, Braden set out to find a better way. That experience became the foundation for Resolve—a company dedicated to helping Americans fight back against unfair medical bills. Since then, Resolve has tackled all types of healthcare billing challenges, partnering with experts across the healthcare ecosystem to reduce financial stress and bring greater transparency to the system.

Brent Lucas is CEO and Board Member of Envoy Medical, an early-stage medical device company pioneering fully implanted hearing solutions, including the Esteem® active middle ear implant and the investigational Acclaim® cochlear implant. A principled medical device executive with a legal background, Brent brings 15+ years of leadership across enterprise functions—spanning strategy, finance, compliance, stakeholder engagement, and product development. Known for his transparent and motivating leadership style, he has guided Envoy through organizational turnaround, fundraising, and global commercialization efforts. With a track record of building inspired teams, streamlining operations, and driving patient-focused innovation, Brent is dedicated to improving quality of life through breakthrough medical technologies.

Brian Newsom is the founding CEO of the vector technology company, Carrigent, as well as the VP of Business Development for the cell therapy CDMO, Theragent. Prior to this, Brian spent six years at KBI Biopharma and almost a decade at Thermo Fisher Scientific (and legacy companies) in business development. Brian’s technical background includes posts as Head of R&D at Opexa Therapeutics and five years at Baylor College of Medicine, Center for Cell and Gene Therapy. Brian began his career in cell therapy at Aastrom Biosciences, one of the industries pioneering companies, in 1992. Brian received his degree in Microbiology from Texas Tech University and an MBA from Texas A&M University.

Dan Goldberger is a highly accomplished C-level executive with over 25 years of leadership experience, known for driving revenue growth and organizational success in the life sciences and healthcare sectors. He has built a strong reputation for leading turnaround initiatives, cultivating high-performance cultures, and spearheading product innovation in competitive, highly regulated industries including biotech, high tech, and medical technology. While his résumé outlines an impressive history of roles and achievements, it does not fully capture the perseverance and dedication he brings to every opportunity. A lifelong contributor to the life sciences and healthcare space, Dan is deeply committed to developing companies and products that improve and save lives—an enduring passion that motivates him to build exceptional teams, processes, and systems that deliver meaningful impact.

David Esposito is an experienced health care executive who has built and scaled multiple companies, resulting in successful exits to strategic buyers. He is the former CEO of Armune BioScience, where he led the development and commercialization of blood-based diagnostics to improve the early detection of cancer. The company successfully launched the only non-PSA blood test to improve the detection of prostate cancer. Armune BioScience was sold to Exact Sciences (EXAS) in 2017. David was president of Phadia US Inc. (allergy and autoimmune diagnostics) and played a pivotal role in the sale of the business to Thermo Fisher Scientific (TMO) in 2011. He began his career as a sales representative with Merck & Co. Inc., rising through the ranks of sales, marketing and commercial strategy for the U.S. division. As a combat veteran, David led an infantry platoon with the 101st Airborne Division through several combat operations and was recognized with a Bronze Star for combat action in Iraq in 1991. He earned his bachelor’s degree in civil engineering from the U.S. Military Academy at West Point and his MBA from Syracuse University.

David Georges has been a global business leader in Breast Imaging for the past twenty-five years, contributing to the introduction and substantial market growth of innovative products dedicated to the early detection of breast cancer including mammography, breast biopsy, computer aided detection, breast ultrasound and automated breast ultrasound. David has established manufacturing sites, supported luminary sites for new product introduction, and established physician and technologist training centers. He has held senior executive positions in companies such as Transworld, Lorad, Hologic, R2, SuperSonic Imagine, iVu and U-systems; the latter of which was purchased by GE. Since joining Koning, David has led the effort to move the company from a Research and Development group to one that is prepared for commercializing Koning’s KBCT. David’s industry relationships have introduced opportunities to establish critically important luminary partners. With a knowledge of global distribution, David has expanded the Koning installation base to Thailand, Qatar, and Netherlands.

Dr. Alena Butkevica, MD, DMD, PhD, is an Oral and Maxillofacial Surgeon and specialist in Prosthodontics and Implantology with over 28 years of clinical experience and more than 15,000 surgical procedures performed; she is also the CEO and founder of AB BIOINNOVATIONS, Inc. (AB BIO), a U.S.-based biotechnology company developing science-backed products that reset, restore, and enhance the body’s natural regenerative abilities by improving circulation, releasing toxins, and accelerating healing—an approach rooted in Dr. Butkevica’s 19 years of scientific research in fast and healthy tissue regeneration.

Dr. Axa Yox is a former scientist turned transformational speaker, author, and LinkedIn strategist. With a PhD in Microbiology and Genetics and a career marked by international fellowships and groundbreaking research, she has authored over 45 scientific papers and holds 12 inventions. Now based in Miami, she’s the founder of X Theory, host of the W.H.Y. – What How Y podcast, and author of Foolfilled Life, a motivational guide to rewiring the brain to overcome anxiety and procrastination. A TEDx 2025 speaker-in-prep and executive contributor at BRAINZ Magazine, Axa brings deep scientific insight to personal development, branding, and the psychology of change.

Over the course of the last decade, first as a graduate student at Harvard University in the Department of Molecular and Cell Biology with PhD advisor Professor Stuart Schreiber and then as an independent postdoctoral fellow at the Lewis-Sigler Institute at Princeton University, Dr. Ethan Perlstein developed an approach to studying old drugs and discovering new drugs in model organisms called evolutionary pharmacology. Ethan is an author on 19 peer-reviewed scholarly publications, including the discovery of a novel mechanism of action for the antidepressant Zoloft based on studies in yeast cells.

Dr. Harsha K. Rajasimha is a scientist, entrepreneur, and patient advocate, and the Founder & CEO of Jeeva Clinical Trials—an AI-driven platform making clinical research more efficient and accessible worldwide. He also serves as Founder and Chair of the Indo US Organization for Rare Diseases, building global collaboration to improve outcomes for patients with rare conditions. Motivated by personal loss, Harsha has dedicated his 20-year career in precision medicine and biotech to advancing rare disease research, patient advocacy, and the use of technology to accelerate clinical trials.

Dr. Josh Funk is the Founder and CEO of Rehab 2 Perform (R2P), a growing performance-based physical therapy company redefining how people experience rehab and recovery. With a model rooted at the intersection of movement, mindset, and long-term performance, Dr. Funk and his team focus on helping clients—from athletes and new moms to first responders and everyday movers—level up, not just heal. Under his leadership, R2P has grown into a multi-location, multi-state business that blends clinical excellence with a community-driven culture. The core philosophy? Treat people like athletes, build a better baseline, and help them perform for life. Dr. Funk also co-leads R2P Academy, an education and mentorship platform for clinicians, intrapreneurs, and future leaders in performance healthcare. A frequent speaker on topics like growth strategy, identity-based care, and scaling with soul, Dr. Funk is passionate about building businesses that make a lasting impact—inside and outside the clinic.

Dr. Kevin Scanlon is a seasoned leader in life sciences, with a career spanning academic medicine, executive roles in biotech and pharma, and active angel investing. Recognized by LA Techweek for his impact on the Los Angeles tech and business landscape, he served as Chairman of the Pasadena Angels, where nearly 100 investors funded over 50 companies during his tenure. Dr. Scanlon has led four biotech companies as CEO, including Melanoma Diagnostics, acquired by Myriad Genetics. At Berlex-Schering AG, he oversaw global genomic and oncology programs across the US, Europe, and Asia. His academic credentials include being a Leukemia Society Scholar, recipient of the Paul Martini Medical Research Prize (Germany), and co-founding editor of Cancer Gene Therapy (Nature Publishing Group). He has served as President of the International Society of Cell and Gene Therapy and authored 139 peer-reviewed papers, nine medical books, and seven U.S. patents. Dr. Scanlon is also the author of The Hybrid Entrepreneur.

UBERDOC Founder and CEO Paula M. Muto, MD FACS, is a practicing vascular and general surgeon in solo practice and the owner of Muto Vein Center. She is a member of a family of physicians and surgeons who have collectively practiced medicine in Massachusetts for over 50 years. She is an outspoken advocate for patient care and is passionate about women’s health issues.

Ed Fleischer is a Quality Control executive with extensive experience leading quality improvement, operational excellence, and compliance initiatives in the biotechnology industry. He brings deep knowledge of biotechnology processes, quality systems, and both domestic and international regulatory requirements. Ed has a strong background in Quality and has worked closely with regulatory agencies including the FDA, EMA, and others. He is also a dedicated leader who prioritizes the development of staff at all levels of the organization.

Eitan Akirav is a seasoned biotech leader with over 17 years of experience bridging scientific innovation and business strategy. From leading global biomarker programs at Cerba Research to launching rapid COVID-19 diagnostics at Enzo, he’s driven impactful solutions across the biotech and healthcare landscape. Earlier in his career at NYU, he secured multimillion-dollar research funding and led clinical trials in autoimmunity. With work featured in PNAS and Nature Immunology, Eitan continues to advance science at the intersection of research, innovation, and real-world application.

Erin Morrow is the Director of Product at Embark Veterinary, where she combines her passion for animals with cutting-edge technology to revolutionize pet care. With over 15 years of experience, she specializes in taking innovative products from initial concept through commercialization across SaaS, biotech, and educational technology sectors. Erin has a proven track record of building high-performing teams that consistently deliver products that users genuinely love. Her unique background includes a Bachelor's in Animal Science and Master's in Conservation Biology, giving her both the scientific rigor and deep empathy for animals and their caretakers that drives her customer-focused approach to product development.

Gautham Pasupuleti is the CEO and Managing Director of Biodesign Innovation Labs, a Bangalore- and Delaware-based medical device and healthcare company developing innovative and affordable critical care solutions. He leads a multidisciplinary team focused on life-saving technologies, including the patented RespirAID device, which supported hospitals across India during COVID-19. Gautham is a recognized innovator, having received awards such as Forbes India’s Ultimate 120 Pioneers of Change, the CISCO Global Problem Solver Pandemic Response Prize, and the Best Campus Startup Innovation Award from IIT Bombay. Previously, he was a researcher at MIT Media Lab and founded CornealX, an AI-based eye care startup now integrated into Biodesign Innovation Labs.

Jessica Gibson is the CEO and Co-Founder of Ariel Precision Medicine, dedicated to delivering innovative technology to advance the art and science of Precision Medicine. Ariel leverages expert systems to accelerate precision medicine across the healthcare ecosystem by linking diagnostics and patient-centered data, uncovering the mechanisms of disease, and developing targeted treatments—fundamentally transforming patients' lives and outcomes. With a strong record of leadership, Jessica brings creative and solution-oriented problem-solving skills to accomplish strategic goals. At Ariel, she applies a broad range of experience across the pharmaceutical, biotechnology, clinical, and research sectors to develop scalable solutions for some of healthcare's most pressing challenges in chronic disease. Highly driven and grounded in a strong foundation of medical sales and marketing, Jessica is committed to collaborative engagement with diverse stakeholders, always with a patient-focused perspective.

Jessicca Rege is a pharmaceutical executive with extensive experience in oncology drug development, from pre-IND through commercialization. She has led R&D, regulatory, and medical affairs teams in both large pharma and biotech, guided in-licensing and acquisition strategies, and worked closely with global regulatory authorities. Jessica is also a trusted voice with investors, scientific leaders, and industry partners, advancing innovative cancer therapies worldwide.

Medical device sales professional that utilizes grit, achievement drive, and organization to achieve success and appropriate solutions for the customer. High achievement with highest revenue, President's Club, etc. Strong leadership skills and desire to facilitate the success of others.

Throughout her career, Kerchanin Allen has supported organizations ranging from startups to Fortune 50 companies in operationalizing their marketing and communications strategies, with a focus on compliance and sustainable growth. In her recent roles, she has emphasized leadership in developing comprehensive, health-centric, and value-based marketing strategies that drive success in post-acute care and align with broader business objectives. Kerchanin works collaboratively with cross-functional teams to refine brand storytelling and develop robust, data-driven content pillars and account-based marketing (ABM) strategies that resonate with target audiences and support growth-focused initiatives. Her expertise also extends to leveraging data analytics for campaign optimization and managing budgets to maximize ROI. With a strong command of digital, print, and media channels, along with a talent for cultivating key partnerships, she plays a vital role in advancing brand presence and market influence.

Kevin Harris is the President and co-founder of CureMetrix. With over 25 years of leadership experience, Harris brings a demonstrated track record of success with particular expertise in new product ideation, implementation, market creation, and launch. As a strategic leader with deep operational expertise, Harris has led companies from inception through fundraising and mergers and acquisitions. At CureMetrix, Harris is responsible for envisioning the AI-based products and services tied to breast cancer and breast arterial calcifications detection that are the foundation of the company’s business and are the first of their kind in the world.

Len May is a pioneer in personalized wellness, combining over 25 years of experience in genomics, epigenetics, and the endocannabinoid system. As the CEO of EndoDNA, he leads the development of a patented platform that uses DNA to deliver personalized health insights, supported by the world’s largest real-world efficacy dataset. A global authority on medicinal cannabis and precision health, Len is also a published author, international speaker, and host of the podcast Everything is Personal. His books Making Cannabis Personal and ADD is a Superpower highlight his commitment to reshaping healthcare through personalization. Len’s work continues to shape the future of individualized medicine, making healthcare truly personal.

The inventor of the ApiJect Platform and its first BFS injection device is Marc Koska, a highly honored “social entrepreneur.” The Prefilled ApiJect Injector is designed for simplicity: Just prior to injection, a fill-finished Blow-Fill-Seal container and intramuscular needle hub are push-twisted together by a healthcare professional. Leading ApiJect R&D, Marc and his team design drug delivery system prototypes that can reliably serve both advanced and developing markets. Through feedback from patients and healthcare providers, Marc has a deep understanding of customers and in building healthcare partnerships. This feedback is the foundation of ApiJect’s Platform to ensure our single-use prefilled injector and future devices meet the needs of all. The ApiJect Platform of drug delivery devices is designed to optimize manufacturing, warehousing, and transportation, using advanced technology, deliver cost efficiencies and accelerating time to market, and most importantly, save lives.

Mary Hames is a scientist-turned-strategic leader with over a decade of experience guiding biotech and pharma companies from breakthrough science to real-world impact. With deep expertise in neurology, rare diseases, and radiopharmaceuticals, Mary has held roles spanning R&D, medical affairs, diagnostics, and executive leadership. She specializes in translating complex science into strategic action—building scalable systems, aligning cross-functional teams, and accelerating development and launch readiness. Known for her clarity, energy, and execution, Mary thrives in high-stakes environments where innovation meets urgency.

Meghna Deshraj is the CEO and Founder of Bullzeye Media Marketing, where she partners with eCommerce brands, healthcare institutions, and small businesses to scale profitably without outside funding. Under her leadership, Bullzeye has driven over $580M in annual growth and more than $1B in collective direct revenue for its clients. With a background spanning corporate strategy, IT, finance, and process optimization, Meghna brings a unique blend of data-driven marketing expertise and operational leadership. A Certified Six Sigma Black Belt with deep experience in program management and business transformation, she has successfully led global teams, large-scale integrations, and organizational change initiatives. Her superpower lies in marketing strategy and consulting, fueled by a passion for helping businesses grow through innovation, efficiency, and strong client relationships.

Naomi Cosman is the Global Head of Marketing at Koning, where she leads the company’s overall marketing strategy, including PR, social media, creative, web, and campaign execution. With a double major in Communications and French from the University of Wisconsin-Madison, Naomi also holds marketing and business certificates from NYU and Harvard Business School. She brings over a decade of experience—five years at a Fortune 500 company in branding and campaign management, followed by five years with startups across various sectors. At Koning, Naomi partners with leadership to elevate brand awareness and public engagement, helping position the company as a leader in revolutionary women’s healthcare.

Real Rousseau is a seasoned business growth strategist with over 20 years of executive leadership experience spanning CEO, COO, and Business Development roles. He specializes in helping companies unlock revenue potential, streamline operations, and lead high-performing sales and marketing teams. Known for delivering measurable results—such as doubling revenue and boosting profit margins by 30% in just 12 months—Real combines strategic vision with operational expertise to drive sustainable business success.

Sarah Bellenger is a clinician, Army veteran, and healthcare leader with over two decades of experience in patient care, team leadership, and system-wide operations. Her career spans cardiac ICU nursing, managing anesthesia teams across the U.S. and abroad, and even supporting executive health at the White House. After earning her MBA and serving in multiple leadership roles, Sarah recognized a recurring problem: capable professionals were burning out—not from the work itself, but from the inefficiencies surrounding it. Driven by her own experiences, including losing critical credentials during frequent relocations, Sarah founded ManageYou—a mobile app that helps healthcare professionals and teams centralize documents, track deadlines, and simplify renewals. Her mission is clear: to reduce administrative burdens so clinicians can focus on what matters most—caring for patients.

Stefan Lukianov is an artist, author, educator, businessman, and scientist with a background in computational bioengineering. He is the founder and CEO of Salve Therapeutics, where he is dedicated to advancing patient care through innovative viral and biologic therapies powered by advanced software solutions. His work centers on patient empowerment, with a focus on leveraging real-time health data and mobile health technologies to improve self-management, independence, and access to care. Beyond his role at Salve, Stefan is a strong advocate for mentorship and collaboration in the biotech industry, aiming to foster innovation, thoughtfulness, and a more patient-centered future for healthcare.

Stephanie Dorwart is the CEO of ALTIUS, a healthcare consulting firm she rebranded and now leads with a hands-on, results-driven approach. With over 15 years of experience in performance improvement and labor management, she’s worked with hospitals of all sizes—from rural facilities to large academic medical centers—helping them improve financial performance, patient outcomes, and staff satisfaction. Known for her analytical expertise and deep industry insight, Stephanie consistently delivers measurable ROI and lasting client impact.

Steve Schutzer is an orthopedic surgeon specializing in adult hip and knee reconstruction, with decades of experience leading joint replacement programs and advancing value-based orthopedic care. He believes in the power of connected communities and digital technologies—especially in today’s accelerating AI environment—working alongside compassionate human caregivers to solve complex medical challenges. Recognized as a focused, innovative, and visionary healthcare physician leader and strategist, Steve has an enduring obsession with improving the patient experience.

Dr. Wendy Slone is the founder and CEO of bTECH Inc., where she leads the development of the Halcyon SMART Patch—a wearable healing technology designed to revolutionize chronic wound care. Inspired by her mother’s experience with diabetic ulcers, Dr. Slone combines personal passion with deep scientific expertise. She holds a Ph.D. in public policy, is pursuing a second doctorate in chemistry, and brings over 15 years of experience in data analytics and entrepreneurship. Her mission is clear: to transform outcomes for patients facing chronic wounds through innovation, science, and purpose-driven leadership.

Yuliana is a seasoned biotech executive and the team’s mission enforcer. After completing her Genetics PhD and post-doctoral research at the universities of Nottingham and Oxford, respectively, she worked in biotech and pharma management consulting, where she helped companies develop their asset commercialization and market access strategies. From 2019 to 2024, Yuliana was part of the executive team at Basepaws, a pet genetics company, acquired by the animal pharma startup Zoetis in 2022. As Basepaws’ Head of R&D, she led the development and refinement of new technologies and scientific products and was a key stakeholder in the translation of scientific discovery into business strategy. Yuliana believes strongly in the power of cross-disciplinary collaboration and innovative thinking to solve the world’s most pressing environmental challenges.